Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT05784441 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05784441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 6, 2023
Completion date
January 3, 2040
Enrollment
21 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b cell non-hodgkin lymphoma